<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Definium Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/definium-therapeutics-inc</link>
<description>Latest news and press releases for Definium Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/definium-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d74a1251cc36e4753339b5.webp</url>
<title>Definium Therapeutics, Inc.</title>
<link>https://6ix.com/company/definium-therapeutics-inc</link>
</image>
<item>
<title>Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day</guid>
<pubDate>Wed, 22 Apr 2026 20:15:00 GMT</pubDate>
<description>NEW YORK, April 22, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and commercial strategy in major depressive disorder (MDD) and generalized anxiety disorder (GAD), with three anticipated topline read</description>
</item>
<item>
<title>Definium Therapeutics to Participate at Upcoming Investor Conferences and Events</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>NEW YORK, April 09, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:</description>
</item>
<item>
<title>New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/new-definium-therapeutics-study-published-in-the-journal-of-mood-and-anxiety-disorders-reveals-increasing-prevalence-and-burden-of-generalized-anxiety-disorder-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/new-definium-therapeutics-study-published-in-the-journal-of-mood-and-anxiety-disorders-reveals-increasing-prevalence-and-burden-of-generalized-anxiety-disorder-in-the-united-states</guid>
<pubDate>Tue, 31 Mar 2026 11:00:00 GMT</pubDate>
<description>NEW YORK, March 31, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and growing burden affecting more than 1 in 10 adults in the U.S. Together, the</description>
</item>
<item>
<title>Definium Therapeutics Announces New Employee Inducement Grants</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-announces-new-employee-inducement-grants-1</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-announces-new-employee-inducement-grants-1</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new</description>
</item>
<item>
<title>Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-host-investor-and-analyst-day-in-new-york-on-april-22-2026</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-host-investor-and-analyst-day-in-new-york-on-april-22-2026</guid>
<pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
<description>NEW YORK, March 26, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026.</description>
</item>
<item>
<title>Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size</description>
</item>
<item>
<title>Definium Therapeutics to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-participate-at-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-participate-at-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:01:00 GMT</pubDate>
<description>NEW YORK, February 24, 2026--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:</description>
</item>
<item>
<title>Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-report-full-year-2025-financial-results-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-to-report-full-year-2025-financial-results-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>NEW YORK, February 19, 2026--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates.</description>
</item>
<item>
<title>Definium Therapeutics Appoints Roger Adsett to Board of Directors</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-appoints-roger-adsett-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-appoints-roger-adsett-to-board-of-directors</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth NEW YORK--(BUSINESS</description>
</item>
<item>
<title>Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-introduces-rerouting-minds-an-educational-campaign-exploring-the-potential-of-pharmaceutical-lysergide-lsd-in-mental-health-care</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-introduces-rerouting-minds-an-educational-campaign-exploring-the-potential-of-pharmaceutical-lysergide-lsd-in-mental-health-care</guid>
<pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, January 20, 2026--Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical LSD in Mental Health Care</description>
</item>
<item>
<title>Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-common-shares-to-trade-under-new-nasdaq-ticker-symbol-dftx-effective-january-15-2026</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/definium-therapeutics-common-shares-to-trade-under-new-nasdaq-ticker-symbol-dftx-effective-january-15-2026</guid>
<pubDate>Tue, 13 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, January 13, 2026--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or "Definium") is updating its previous announcement that the Company’s Common Shares would begin trading on Nasdaq under the ticker symbol "DFTX" effective at market open on January 13, 2026. The Company now expects its Common Shares to begin trading on Nasdaq under the ticker symbol "DFTX" effective at market open on January 15, 2026. There is no action required by the Company’s share</description>
</item>
<item>
<title>MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026</title>
<link>https://6ix.com/company/definium-therapeutics-inc/news/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026</link>
<guid isPermaLink="true">https://6ix.com/company/definium-therapeutics-inc/news/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, January 12, 2026--MindMed Announces Rebrand to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026</description>
</item>
</channel>
</rss>